Myelitis

Inflammation of the spinal cord. Relatively common etiologies include infections; AUTOIMMUNE DISEASES; SPINAL CORD; and ischemia (see also SPINAL CORD VASCULAR DISEASES). Clinical features generally include weakness, sensory loss, localized pain, incontinence, and other signs of autonomic dysfunction.

Subtype terms (3)

More specific conditions that are subtypes of Myelitis in the MeSH hierarchy.

Myelitis, Transverse
9 drugs (5 approved, 4 experimental)
Paraparesis, Tropical Spastic
12 drugs (11 approved, 1 experimental)
Poliomyelitis
55 drugs (32 approved, 23 experimental)

Drugs by status

Phase 4 trials (3)

methylprednisolone
naltrexone
interferon beta-1b

Phase 2 trials (1)

dalfampridine

Phase 1 trials (1)

abx-1431

Organizations

Organization Involved with Phase 4 Indications (6)

Merck Serono
Biogen
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Harvard University
State University of New York
Baird Multiple Sclerosis Center

Organization Involved with Phase 3 Indications (12)

University of London
Newcastle University
NHS Lothian
University of Liverpool
University of Manchester
University of Nottingham
University of Birmingham
University of Bristol
Cardiff University
Salford Royal Foundation NHS Trust
University of Oxford
Moorgreen Hospital, Southampton

Organization Involved with Phase 2 Indications (3)

Acorda Therapeutics
Q Therapeutics, Inc.
Johns Hopkins University

Organization Involved with Phase 1 Indications (1)

Abide Therapeutics